Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
Results from a clinical trial have revealed nearly one third (29.2 per cent) of patients with advanced melanoma saw their tumours disappear completely on scans after receiving lifileucel TIL therapy […]
ESMO Congress 2026
The ESMO Congress is a highly influential global oncology meeting for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO 2026 will be a […]
